PATENT CLAIM ANALYSIS

Application Number: 16237893
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-04
Patent Classification: ["530", "326000"]

Abstract:
The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Claim (Index 7):
The C5 inhibitor polypeptide of  claim 6 , wherein the polypeptide of R 2  comprises the formula Xaa8-Xaa9-Xaa10-Xaa11, wherein:\n Xaa8 is selected from the group consisting of Trp, Tyr, Phe, 2-naphthylalanine, and meta-chloro homophenylalanine; Xaa9 is selected from the group consisting of Pro, N-methyl-Gly, and Ala, or is absent; Xaa10 is selected from the group consisting of cyclohexylglycine and norvaline, or is absent; and Xaa11 is selected from the group consisting of norvaline and N-methyl-serine, or is absent.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 99.0
- Lexical Diversity: 1.17647
- Patent Class: 530.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16128561', '15318063', '15905158', '15547085', '14962457']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8381055017215653
- 35 USC 102 Novelty (BERT): 0.5954354452764783
- Combined Prediction Score: 0.8138384960770566
- Mean Citation Score: 504.10272
- Max Citation Score: 611.3871
- Similarity Product: 391.31929360249046

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test